submit to the journals

Parkinson's Disease Journal Articles, Videos And Insights

Parkinson's Disease:FEATURED Articles

flipper_slider

Parkinson's Disease: Latest Articles

Parkinson's Disease: INSIGHTS

The touchNEUROLOGY website provides a selection of resources to inform clinicians and patients about the latest developments in the field. The following are quick, non peer-reviewed, opinion-based updates addressing current trends and opinion on the most recent advances in the area of neurology:

Insight
Highlights of the EAN Congress 2018 – focus on Parkinson’s disease

Katrina Mountfort, Freelance Medical Writer for Touch Medical Media, UK
Jon Shepheard, Neurology Account Director, Touch Medical Media, UK
-Insights into Parkinson’s disease presented at the 4th Congress of the European Academy of Neurology (EAN), Lisbon, Portugal, 16–19 June 2018

Parkinson's Disease:FEATURED VIDEOS

Editor's choice

Daniel Kremens (Sidney Kimmel Medical College, Thomas Jefferson University) discusses his recently published article co-authored with Stuart Isaacson, entitled: Treatment Advances in Parkinson’s Disease Psychosis—Transforming the Standard of Care for Hallucinations and Delusions. In this report, they explore the pathophysiology, symptomology, diagnosis and impact of Parkinson's disease psychosis (PDP), the role of serotonin signaling within PDP, and examine the current standard of care for treatment for the condition. The full article can be viewed here. Questions 1. How does Parkinson’s disease psychosis (PDP) differ from other psychotic disorders? (0:11) 2. What are the pathophysiological mechanisms underlying the development of PDP? (1:12) 3. What is the major limitation of atypical antispychotic drugs in treating patients with PDP? (2:32) 4. What clinical evidence supports the use of pimavenserin for PDP? (3:29) Speaker disclosures: Daniel Kremens has worked as a consultant for ACADIA, Teva, GE Healthcare, US WorldMeds, Impax, UCB, Kyowa, Acorda, Sunovion, St. Jude Medical, Adamas, Neurocrine and Prexton Therapeutics; received speaker’s honoraria for ACADIA, Teva, US WorldMeds, Impax, and UCB; and received research funding from Civitas and Enterin. Filmed at the American Academy of Neurology (AAN) Annual Meeting 2018, Los Angeles, CA, US, April 2018, with support from ACADIA Pharmaceuticals Inc.
K Ray Chaudhuri (Professor of Movement Disorders, Neuroscience Research and Development, King's College; Director, King’s Parkinson’s Centre, King’s College Hospital, London, UK) considers the major societal burden of Parkinson's disease (PD) and what early symptoms doctors should be on the lookout for to improve early detection. Questions 1. Could you tell us a little about the societal burden of PD? (0:12) 2. What early symptoms of PD should doctors be looking for? (1:26) 3. How else can we improve the early detection of PD? (2:57) Speaker disclosure: K Ray Chaudhuri has nothing to disclose in relation to this video interview. Filmed at the 4th Congress of the European Academy of Neurology (EAN), Lisbon, Portugal, June 2018.

Parkinson's Disease:Latest Videos

Video List based on Category on Node Page

Latest Videos

Chair of the IAPRD 2018 Scientific Program Executive Committee, Hubert Fernandez (Cleveland Clinic, Cleveland, OH, US), discusses identification of patients with Parkinson's disease (PD) at risk of cognitive decline, the advantages of levodopa-carbidopa intestinal gel in advanced PD, recent...
IAPRD 2018 Congress Chair, Elena Moro (Grenoble University, Grenoble, France), shares her highlights from the meeting including discussion of unmet needs in the treatment of Parkinson's disease (PD), management of gait and postural disturbances in advanced PD, pedunculopontine nucleus deep brain...
K Ray Chaudhuri (Professor of Movement Disorders, Neuroscience Research and Development, King's College; Director, King’s Parkinson’s Centre, King’s College Hospital, London, UK) discusses the major unmet needs in the care of patients with advanced Parkinson's disease (PD) and at what stage...
K Ray Chaudhuri (Professor of Movement Disorders, Neuroscience Research and Development, King's College; Director, King’s Parkinson’s Centre, King’s College Hospital, London, UK) considers the major societal burden of Parkinson's disease (PD) and what early symptoms doctors should be on the...
Pille Taba (EAN Programme Committee and Teaching Course Sub-committee; MDS-ES Representative; Professor of Neurology, Department of Neurology and Neurosurgery, University of Tartu, Estonia) tells us what she considers major challenges and important developments in Parkinson's...
Rajesh Pahwa (University of Kansas Medical Center) discusses the management of dyskinesia in Parkinson's disease with a focus on amantadine (GOCOVRI™), the first and only FDA-approved medication for this indication. Questions 1. What is the mechanism of action of amantadine in dyskinesia?...

LATEST TWEETS

Conference Highlights